Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock. The post Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade appeared first on Investor's Business Daily.
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
The post Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
